|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
We demonstrate the usefulness of synthetic lethal screening of a conditionally BCL6-deficient Burkitt lymphoma cell line, DG75-AB7, with a library of small molecules to determine survival pathways suppressed by BCL6 and suggest mechanism-based treatments for lymphoma.
|
27268052 |
2016 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Previous studies have suggested that NF-kappaB activity is suppressed in germinal center and lymphoma B cells that express high levels of BCL-6, and yet the reason for this is unknown.
|
15611242 |
2005 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
High grade B-cell lymphoma (HGBCL) by WHO 2016 classification requires rearrangements of MYC and BCL2 and/or BCL6, practically covering the so called "double-hit" or "triple hit" lymphomas.
|
29666005 |
2018 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
BCL2/MYC DH lymphomas constituted the majority of these DH lymphomas (17 cases; 77%), followed by BCL6/MYC (2 cases; 9%) lymphomas.
|
26224092 |
2015 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
As BCL6 plays a central role in the pathogenesis of diffuse large B-cell lymphoma, we predict that targeting BCL6 transcriptional repression complexes in malignant B-cells may constitute a novel form of transcription therapy for lymphomas and possibly other tumors.
|
15655367 |
2005 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The BCL-6 protein is a potent transcriptional repressor which presumably controls lymphocyte differentiation and induces lymphomas by regulating the expression of key downstream target genes.
|
10626250 |
1999 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements, so-called "double-hit" lymphomas (HGBL-DH), are aggressive lymphomas that form a separate provisional entity in the 2016 revised World Health Organization Classification of Lymphoid Tumors.
|
27821509 |
2017 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Lymphomas with MYC and either BLC2 or BCL6 rearrangements or MYC and BCL-2 protein overexpression, classified as double-hit (DHL) or double-expressor (DEL) lymphomas, respectively, are associated with poorer response to standard immunochemotherapy.
|
29722657 |
2018 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Rearrangement of the bcl-6 gene correlated with a favorable clinical outcome in DLLC and may thus serve as a prognostic marker in patients with this form of malignant lymphoma.
|
8208268 |
1994 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
The present progress may have direct implications for breast cancer progression and therapy as loss of prolactin receptor-Stat5 signaling occurs frequently and BCL6 inhibitors currently being evaluated for lymphomas may have value for breast cancer.
|
23708665 |
2014 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Immunophenotypic and genotypic markers used to suggest a FCC origin for a lymphoma (bcl-6 and CD10 expression, lack of CD138 expression, bcl-2 rearrangements [R]) or to subdivide DLBCL (bcl-2 expression, bcl-6 R) were therefore investigated in 22 FL and 44 DLBCL using paraffin section immunostains and Southern blot/polymerase chain reaction analysis.
|
11106080 |
2000 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The median cytogenetic complexity score was 2.5 (range, 0 to 14) in 14 evaluable mature aggressive lymphomas with an immunoglobulin gene partner for MYC in 9/14 and for BCL6 in 7/14 cases.
|
23348205 |
2013 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Double-color FISH with IgH (Y6) and BCL6 (cosB5-1) showed fusion of BCL6 and IgH genes on der(3)t(3;14) in all nine patients, suggesting that der(3) may play a critical role in the development of lymphoma carrying complex as well as standard t(3;14) translocations.
|
9398863 |
1997 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Because BCL6 expression has been reported in a number of T cell tumors as well as in the more commonly occurring B cell lymphomas in humans, our transgenic mice provide a model for the study of human lymphomas.
|
15375218 |
2004 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
There were 14 cases (14.29%, 14/98) and 34 cases (34.70%, 34/98) of lymphomas with the DHL and DEL of MYC and BCL2/BCL6, respectively.
|
31615842 |
2020 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
BCL6 antagonists are active against primary DLBCL and may find future application in the treatment of lymphomas.
|
21083654 |
2011 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement.
|
8703825 |
1996 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
|
27717585 |
2017 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
However BCL6 also directly represses several DLBCL oncogenes such as BCL2 and BCL-XL that promote lymphoma survival.
|
26657288 |
2016 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Whether these lymphomas arose from T cells expressing BCL-6 or expressed BCL-6 as part of the malignant transformation process needs to be determined.
|
11742039 |
2001 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.
|
12217802 |
2002 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
The identification of BCL-6 ABR provides new tools for the diagnosis of lymphomas carrying aberrations at 3q27 and deregulated BCL-6 genes.
|
12124346 |
2002 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Patients with both MYC and BCL2 CNA had similar outcomes to those with classic double hit lymphoma or protein double expression lymphoma (MYC and BCL2/BCL6 coexpression).
|
26158410 |
2015 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
LHGDN |
We found that activation of STAT5 downregulates BCL6 expression in B-lymphoma cells and other hematopoietic cell lines.
|
16819511 |
2007 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Several experiments and mouse models mimicking BCL6 translocation occurring in human lymphoma have demonstrated the oncogenic role of BCL6 and constitute a rational to consider BCL6 as a new therapeutic target in NHL.
|
16815642 |
2007 |